Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
114 hedge funds and large institutions have $430M invested in Five Prime Therapeutics, Inc. in 2018 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 34 reducing their positions, and 27 closing their positions.
29% more call options, than puts
Call options by funds: $2.14M | Put options by funds: $1.66M
21% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 34
7% less funds holding
Funds holding: 123 → 114 (-9)
12% less capital invested
Capital invested by funds: $490M → $430M (-$60.7M)
33% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$33.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.77M |
| 3 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$4.02M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.79M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.5M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$17.4M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$15.5M |
| 4 |
State Street
Boston,
Massachusetts
|
-$5.72M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$2.9M |
FPRX Hedge Fund Activity: Q3 2018 in Review
114 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2018, worth a combined $430M — down 12% from $490M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of FPRX and 18 opened new positions — a net loss of 9 holders — while 34 trimmed existing stakes and 41 added.
The largest buyer was BVF Inc, adding an estimated $33.5M. The largest seller was Fidelity Investments, cutting an estimated $18.5M.
- 114 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2018, down from 123 in Q2 2018.
- Funds reported $430M of Five Prime Therapeutics, Inc. stock for Q3 2018, down 12% quarter-over-quarter.
- 18 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2018 and 27 closed out, a net change of -9 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q3 2018 was BVF Inc, an estimated $33.5M added.
- The largest Five Prime Therapeutics, Inc. seller in Q3 2018 was Fidelity Investments, an estimated $18.5M sold.
Based on aggregated 13F filings for Q3 2018.